Skip to main content

Advertisement

Contact Noboru Nakaigawa

From: FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma

Contact corresponding author